Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing: A randomized phase 3 trial

Hyo Joon Yang, Dong Il Park, Soo Kyung Park, Chang Kyun Lee, Hyo Jong Kim, Shin Ju Oh, Jung Rock Moon, Beom Jae Lee, Jin Sung Koh, Hyun Soo Kim, Seon Young Park, Dong Hyun Kim, Jaeyoung Chun, Eun Ae Kang, Jung Kim, Hosim Soh, Chang Soo Eun, You Sun Kim, Yoon Tae Jeen

Research output: Contribution to journalArticle

Abstract

Background and Aim: PBK-1701TC is a novel sulfate tablet-based that contains 320 mg of simethicone and delivers 90% of the salt and water delivered by oral sulfate solution (OSS) preparation. This study evaluated the efficacy, safety, and tolerability of PBK-1701TC compared with OSS in bowel preparation for colonoscopy. Methods: This randomized, multicenter, phase 3 non-inferiority trial included adults aged 19 years or older with a body mass index of 19–30 kg/m2 undergoing colonoscopy at five university hospitals in Korea. The primary efficacy endpoint was successful bowel-cleansing rate, defined as Harefield Cleansing Scale grade A or B as evaluated by blinded central readers. Secondary endpoints included the presence of residual air bubbles. Adverse events and laboratory evaluations were monitored to assess safety. Tolerability was assessed via participant interview. Results: Overall, 235 participants were randomized, and 224 were included in the per-protocol analysis (PBK, 112; OSS, 112). Successful bowel cleansing was achieved for 95.5% (107/112) in the PBK group, which was non-inferior to the OSS group (98.2%, 110/112) with a difference of −2.7% (one sided 97.5% confidence limit, −8.1%). The participants in the PBK group had fewer intraluminal bubbles (0.9% vs 81.3%, P < 0.001) and reported a lower incidence of nausea and vomiting, with better acceptance, taste, and willingness to repeat the regimen than those in the OSS group (all P < 0.05). Conclusion: The novel sulfate tablet, PBK-1701TC, was non-inferior to OSS with respect to bowel-cleansing efficacy and exhibited better safety and tolerability in adults undergoing colonoscopy.

Original languageEnglish
Pages (from-to)29-36
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume35
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Fingerprint

Tablets
Sulfates
Colon
Colonoscopy
Safety
Simethicone
Cathartics
Korea
Nausea
Vomiting
Body Mass Index
Salts
Air
Interviews
Water
Incidence

Keywords

  • cathartics
  • colonoscopy
  • simethicone
  • sulfates
  • tablets

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing : A randomized phase 3 trial. / Yang, Hyo Joon; Park, Dong Il; Park, Soo Kyung; Lee, Chang Kyun; Kim, Hyo Jong; Oh, Shin Ju; Moon, Jung Rock; Lee, Beom Jae; Koh, Jin Sung; Kim, Hyun Soo; Park, Seon Young; Kim, Dong Hyun; Chun, Jaeyoung; Kang, Eun Ae; Kim, Jung; Soh, Hosim; Eun, Chang Soo; Kim, You Sun; Jeen, Yoon Tae.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 35, No. 1, 01.01.2020, p. 29-36.

Research output: Contribution to journalArticle

Yang, HJ, Park, DI, Park, SK, Lee, CK, Kim, HJ, Oh, SJ, Moon, JR, Lee, BJ, Koh, JS, Kim, HS, Park, SY, Kim, DH, Chun, J, Kang, EA, Kim, J, Soh, H, Eun, CS, Kim, YS & Jeen, YT 2020, 'Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing: A randomized phase 3 trial', Journal of Gastroenterology and Hepatology (Australia), vol. 35, no. 1, pp. 29-36. https://doi.org/10.1111/jgh.14826
Yang, Hyo Joon ; Park, Dong Il ; Park, Soo Kyung ; Lee, Chang Kyun ; Kim, Hyo Jong ; Oh, Shin Ju ; Moon, Jung Rock ; Lee, Beom Jae ; Koh, Jin Sung ; Kim, Hyun Soo ; Park, Seon Young ; Kim, Dong Hyun ; Chun, Jaeyoung ; Kang, Eun Ae ; Kim, Jung ; Soh, Hosim ; Eun, Chang Soo ; Kim, You Sun ; Jeen, Yoon Tae. / Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing : A randomized phase 3 trial. In: Journal of Gastroenterology and Hepatology (Australia). 2020 ; Vol. 35, No. 1. pp. 29-36.
@article{0dd4c730964048dfbb1426ecb1623f43,
title = "Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing: A randomized phase 3 trial",
abstract = "Background and Aim: PBK-1701TC is a novel sulfate tablet-based that contains 320 mg of simethicone and delivers 90{\%} of the salt and water delivered by oral sulfate solution (OSS) preparation. This study evaluated the efficacy, safety, and tolerability of PBK-1701TC compared with OSS in bowel preparation for colonoscopy. Methods: This randomized, multicenter, phase 3 non-inferiority trial included adults aged 19 years or older with a body mass index of 19–30 kg/m2 undergoing colonoscopy at five university hospitals in Korea. The primary efficacy endpoint was successful bowel-cleansing rate, defined as Harefield Cleansing Scale grade A or B as evaluated by blinded central readers. Secondary endpoints included the presence of residual air bubbles. Adverse events and laboratory evaluations were monitored to assess safety. Tolerability was assessed via participant interview. Results: Overall, 235 participants were randomized, and 224 were included in the per-protocol analysis (PBK, 112; OSS, 112). Successful bowel cleansing was achieved for 95.5{\%} (107/112) in the PBK group, which was non-inferior to the OSS group (98.2{\%}, 110/112) with a difference of −2.7{\%} (one sided 97.5{\%} confidence limit, −8.1{\%}). The participants in the PBK group had fewer intraluminal bubbles (0.9{\%} vs 81.3{\%}, P < 0.001) and reported a lower incidence of nausea and vomiting, with better acceptance, taste, and willingness to repeat the regimen than those in the OSS group (all P < 0.05). Conclusion: The novel sulfate tablet, PBK-1701TC, was non-inferior to OSS with respect to bowel-cleansing efficacy and exhibited better safety and tolerability in adults undergoing colonoscopy.",
keywords = "cathartics, colonoscopy, simethicone, sulfates, tablets",
author = "Yang, {Hyo Joon} and Park, {Dong Il} and Park, {Soo Kyung} and Lee, {Chang Kyun} and Kim, {Hyo Jong} and Oh, {Shin Ju} and Moon, {Jung Rock} and Lee, {Beom Jae} and Koh, {Jin Sung} and Kim, {Hyun Soo} and Park, {Seon Young} and Kim, {Dong Hyun} and Jaeyoung Chun and Kang, {Eun Ae} and Jung Kim and Hosim Soh and Eun, {Chang Soo} and Kim, {You Sun} and Jeen, {Yoon Tae}",
year = "2020",
month = "1",
day = "1",
doi = "10.1111/jgh.14826",
language = "English",
volume = "35",
pages = "29--36",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing

T2 - A randomized phase 3 trial

AU - Yang, Hyo Joon

AU - Park, Dong Il

AU - Park, Soo Kyung

AU - Lee, Chang Kyun

AU - Kim, Hyo Jong

AU - Oh, Shin Ju

AU - Moon, Jung Rock

AU - Lee, Beom Jae

AU - Koh, Jin Sung

AU - Kim, Hyun Soo

AU - Park, Seon Young

AU - Kim, Dong Hyun

AU - Chun, Jaeyoung

AU - Kang, Eun Ae

AU - Kim, Jung

AU - Soh, Hosim

AU - Eun, Chang Soo

AU - Kim, You Sun

AU - Jeen, Yoon Tae

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background and Aim: PBK-1701TC is a novel sulfate tablet-based that contains 320 mg of simethicone and delivers 90% of the salt and water delivered by oral sulfate solution (OSS) preparation. This study evaluated the efficacy, safety, and tolerability of PBK-1701TC compared with OSS in bowel preparation for colonoscopy. Methods: This randomized, multicenter, phase 3 non-inferiority trial included adults aged 19 years or older with a body mass index of 19–30 kg/m2 undergoing colonoscopy at five university hospitals in Korea. The primary efficacy endpoint was successful bowel-cleansing rate, defined as Harefield Cleansing Scale grade A or B as evaluated by blinded central readers. Secondary endpoints included the presence of residual air bubbles. Adverse events and laboratory evaluations were monitored to assess safety. Tolerability was assessed via participant interview. Results: Overall, 235 participants were randomized, and 224 were included in the per-protocol analysis (PBK, 112; OSS, 112). Successful bowel cleansing was achieved for 95.5% (107/112) in the PBK group, which was non-inferior to the OSS group (98.2%, 110/112) with a difference of −2.7% (one sided 97.5% confidence limit, −8.1%). The participants in the PBK group had fewer intraluminal bubbles (0.9% vs 81.3%, P < 0.001) and reported a lower incidence of nausea and vomiting, with better acceptance, taste, and willingness to repeat the regimen than those in the OSS group (all P < 0.05). Conclusion: The novel sulfate tablet, PBK-1701TC, was non-inferior to OSS with respect to bowel-cleansing efficacy and exhibited better safety and tolerability in adults undergoing colonoscopy.

AB - Background and Aim: PBK-1701TC is a novel sulfate tablet-based that contains 320 mg of simethicone and delivers 90% of the salt and water delivered by oral sulfate solution (OSS) preparation. This study evaluated the efficacy, safety, and tolerability of PBK-1701TC compared with OSS in bowel preparation for colonoscopy. Methods: This randomized, multicenter, phase 3 non-inferiority trial included adults aged 19 years or older with a body mass index of 19–30 kg/m2 undergoing colonoscopy at five university hospitals in Korea. The primary efficacy endpoint was successful bowel-cleansing rate, defined as Harefield Cleansing Scale grade A or B as evaluated by blinded central readers. Secondary endpoints included the presence of residual air bubbles. Adverse events and laboratory evaluations were monitored to assess safety. Tolerability was assessed via participant interview. Results: Overall, 235 participants were randomized, and 224 were included in the per-protocol analysis (PBK, 112; OSS, 112). Successful bowel cleansing was achieved for 95.5% (107/112) in the PBK group, which was non-inferior to the OSS group (98.2%, 110/112) with a difference of −2.7% (one sided 97.5% confidence limit, −8.1%). The participants in the PBK group had fewer intraluminal bubbles (0.9% vs 81.3%, P < 0.001) and reported a lower incidence of nausea and vomiting, with better acceptance, taste, and willingness to repeat the regimen than those in the OSS group (all P < 0.05). Conclusion: The novel sulfate tablet, PBK-1701TC, was non-inferior to OSS with respect to bowel-cleansing efficacy and exhibited better safety and tolerability in adults undergoing colonoscopy.

KW - cathartics

KW - colonoscopy

KW - simethicone

KW - sulfates

KW - tablets

UR - http://www.scopus.com/inward/record.url?scp=85074439032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074439032&partnerID=8YFLogxK

U2 - 10.1111/jgh.14826

DO - 10.1111/jgh.14826

M3 - Article

C2 - 31396995

AN - SCOPUS:85074439032

VL - 35

SP - 29

EP - 36

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 1

ER -